Drugs / Live attenuated tetravalent dengue vaccine
Live attenuated tetravalent dengue vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00239577 | Apr 2006 → Jun 2007 | dengue disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live attenuated tetravalent dengue vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00239577 ↗ |
| Modality | Vaccine | “Live attenuated tetravalent dengue vaccine” NCT00239577 ↗ |
| Route | Subcutaneous | “administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm” NCT00239577 ↗ |